Other Clinical Trial - Clinical Endpoint Study of Ivermectin 1% Cream

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03050086` - Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea	Phase 1/Phase 2

NCT number	NCT02840461
Study type	Interventional
Source	Actavis Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	June 2016
Completion date	December 2016

Clinical Endpoint Study of Ivermectin 1% Cream

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms